FDA Approves Simtriyo for ADHD Treatment in Landmark Drug Decision
The FDA approved Simtriyo (centanafadine), a new medication for treating attention-deficit hyperactivity disorder, on July 24, 2026. This represents a major advance in ADHD treatment options available to patients.
FDA Approval Marks New ADHD Treatment Option
The FDA approved Simtriyo (centanafadine) for the treatment of attention-deficit hyperactivity disorder on July 24, 2026. The approval represents a significant milestone in pharmaceutical treatment options for ADHD, a condition affecting millions of individuals globally.
What Centanafadine Does
Centanafadine joins an existing arsenal of ADHD medications, offering patients and clinicians another therapeutic pathway. The drug's approval follows clinical trial evaluation demonstrating efficacy and safety profiles acceptable to the FDA's rigorous standards.
Market Impact and Significance
The addition of centanafadine to the ADHD treatment landscape diversifies options for patients who may not respond adequately to existing therapies or experience adverse effects. Healthcare providers now have another tool in their clinical toolkit to tailor treatment plans to individual patient needs and circumstances.
Patient Access and Next Steps
With FDA approval, Simtriyo can now be prescribed by healthcare providers to eligible ADHD patients. Insurance coverage, pricing, and availability through pharmacies will depend on individual payer policies and distribution agreements. This approval underscores the continued evolution of neuropsychiatric medication development.